Valeo Financial Advisors LLC Has $4.76 Million Holdings in Pfizer Inc. (NYSE:PFE)

Valeo Financial Advisors LLC lessened its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 7.4% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 187,780 shares of the biopharmaceutical company's stock after selling 14,925 shares during the quarter. Valeo Financial Advisors LLC's holdings in Pfizer were worth $4,758,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Bessemer Group Inc. raised its position in Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock worth $3,358,000 after acquiring an additional 13,228 shares in the last quarter. CHURCHILL MANAGEMENT Corp bought a new stake in Pfizer during the first quarter worth $8,283,000. Capital Advisors Inc. OK raised its position in Pfizer by 1.2% during the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company's stock worth $35,817,000 after acquiring an additional 17,032 shares in the last quarter. Alta Advisers Ltd raised its position in shares of Pfizer by 69.6% in the first quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock valued at $809,000 after purchasing an additional 13,100 shares during the period. Finally, WCM Investment Management LLC raised its position in shares of Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock valued at $3,176,000 after purchasing an additional 10,051 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Up 1.1%

Pfizer stock opened at $25.52 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The company has a market capitalization of $145.11 billion, a P/E ratio of 18.50, a PEG ratio of 0.92 and a beta of 0.58. The stock has a 50-day simple moving average of $23.76 and a 200-day simple moving average of $24.81.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's quarterly revenue was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.82 EPS. Equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.74%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Analysts Set New Price Targets

PFE has been the topic of a number of recent research reports. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. HSBC reduced their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research note on Monday, May 19th. Citigroup increased their price objective on shares of Pfizer from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Bank of America increased their price objective on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, BMO Capital Markets reduced their price objective on shares of Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.